Endoluten
The Khavinson pineal bioregulator preparation, positioned as a "precursor/complementary" product to epithalon (the synthetic AEDG tetrapeptide). Marketed in Russia for neuroendocrine and circadian support in aging. Evidence base is Russian-language Khavinson-group studies with minimal independent replication.
A pineal-gland-derived short peptide preparation in the Khavinson cytomedine series, marketed as Endoluten in Russia and CIS markets. Positioned as the natural-extract counterpart to the synthetic tetrapeptide epithalon (Ala-Glu-Asp-Gly / AEDG), which was itself isolated from pineal bioregulator preparations in the 1980s. The regulatory and evidentiary profile is identical to other Khavinson natural-extract cytomedines: Russian nutraceutical status, no FDA/EMA approval, and limited Western peer-reviewed validation.
Mechanism of action
Proposed to support pineal-axis function and melatonin-related signaling by providing pineal-tissue-specific short peptides. The active tetrapeptide characterized from pineal extracts is epithalon (AEDG), which has been reported in Khavinson-group studies to induce telomerase activity, extend replicative lifespan in cell culture, and modestly extend lifespan in rodent models. As with other Khavinson claims, extensions to humans rest on small, methodologically limited Russian clinical studies and require independent replication.
Primary uses
- Neuroendocrine aging support (Russian nutraceutical positioning)
- Circadian rhythm / sleep-quality support (anecdotal)
- Immune-senescence support (Russian clinical positioning)
Typical dosing
The amounts in circulation come from the maker's directions, not a controlled study, so no amount is printed here.
Regulatory status
Not FDA- or EMA-approved. Sold in Russia and CIS markets as a nutraceutical supplement, not a registered medicine. The synthetic tetrapeptide epithalon, derived from characterization of pineal bioregulator preparations, is itself a research-only compound and is covered in its own encyclopedia entry.
Status as of this entry's last review, April 19, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
Endoluten is a Russian pineal 'bioregulator' preparation from Vladimir Khavinson's product family, positioned alongside epitalon. Its composition is not disclosed in a form we could check; this section records what can be checked.
Identity, computed
| Sequence | Not established |
The product is described as a pineal extract, not a defined peptide, so no formula or mass can be computed. Epitalon (Ala-Glu-Asp-Gly) is the defined synthetic tetrapeptide associated with it and has its own entry.
Regulatory status, read October 5, 2026
Drugs@FDA: 0 records for “endoluten”. EMA medicines list: 0 records for “endoluten”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from bioregulator sellers: Endoluten normalises melatonin, sleep and ageing. No controlled human study of the product was found.
About pineal peptides and epitalon
The 2007 report on our epitalon entry describes pineal peptide preparations raising night-time melatonin in elderly people; it gives no sleep outcomes or placebo group. Our peptides for sleep article covers that evidence.
What we looked for and did not find
No controlled human study of Endoluten, no defined composition, no registry record and no drug application.
| Source | Query | Results, October 5, 2026 | What it was |
|---|---|---|---|
| PubMed | endoluten | 0 | |
| PubMed | epithalamin pineal peptide preparation | 26 | |
| ClinicalTrials.gov | endoluten | 0 | |
| Drugs@FDA (openFDA) | endoluten | 0 | |
| EMA medicines list | endoluten | 0 |
References
- [pubmed] Khavinson VK, et al. "Peptide extension of lifespan and normalization of physiological functions in aged mice." Bull Exp Biol Med, 2011;151:480-483.
- [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149. PMID: 19830585.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.